Cleveland Clinic launches partnership focused on AI-powered TAVR planning
Cleveland Clinic, one of the world’s top heart hospitals, has launched a new two-part partnership with Ohio-based DASI Simulations.
DASI Simulations has emerged in recent years as a major voice in the artificial intelligence (AI) market. It is known for PrecisionTAVI and DASI Dimensions, two FDA-approved offerings designed to help care teams plan ahead of TAVR and other structural heart procedures. These programs use patient data, including imaging results, to simulate multiple valve deployment scenarios and offer device-agnostic care recommendations.
For the first phase of this partnership, Cleveland Clinic is clinically validating DASI Simulations to model its own TAVR procedures. Cleveland Clinic’s clinicians are still providing care like normal, but they are also reviewing the DASI Simulations predictive models simultaneously to evaluate the technology’s potential.
The next phase will be a full collaboration as Cleveland Clinic’s structural heart specialists work together with DASI Simulations to develop a new intraoperative version of the DASI Simulations product.
“AI is becoming a very important tool for procedural planning in structural cardiology,” Samir Kapadia, MD, chair of cardiovascular medicine at Cleveland Clinic and a leading voice in interventional cardiology, said in a statement. “Our work with DASI Simulations is aimed at clinically validating the use of their technology for TAVR planning and then breaking new ground by using AI for execution of the TAVR procedure rather than just procedural planning.”
“Predictive modeling is all about simplification and personalization of TAVR planning, as it offers recommendations tailored to each patient’s anatomy,” added Grant Reed, MD, MSc, an interventional cardiologist with Cleveland Clinic. “We now have a DASI report generated for all our TAVR patients, and we review those reports individually and then also collectively at our heart team meetings. There have been instances where the simulation has prompted us to change care for patients, particularly when weighing TAVR vs. surgery in the context of trying to envision optimal lifetime management for a given patient.”
Reed praised PrecisionTAVI’s ability to evaluate each patient’s potential risk of coronary obstruction. He also said the technology helps cardiologists “think two steps ahead” by considering the possibility of valve-in-valve TAVR before even performing an initial TAVR procedure.
In addition to this new partnership, Cleveland Clinic is also an investor in DASI Simulations.
Back in October, Medtronic announced its own collaboration with DASI Simulations as well.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.